Abstract
Injectable liposomes are well known in the pharmaceutical industry for drug
delivery. In particular, PEG-coated liposomes have found application for reason of their
increased circulation time, which is believed to be associated with their low tendency to
be opsonized. However, much of the drug never reaches the intended target site. In this
study, methods for binding liposomes onto surfaces ofbiomaterials and biomedical
devices were developed and applied for controlled local delivery of drugs adjacent to
implanted biomedical devices. In this way the aim was to reduce drug amounts and
wastage, and control the local host response to the implant, a response which with most
current biomaterials typically is dominated by fibrous tissue encapsulation.
Liposomes with encapsulated drugs and model substances were produced and
characterized in terms of size and release performance, and bound onto polymeric
surfaces. PEGylated phospholipid liposomes were produced by extrusion through
polycarbonate membranes of various pore sizes. The diameters (mean and distribution)
of the liposomes were characterized by photon correlation spectroscopy. For binding
liposomes, polymer surfaces were coated with NeutrAvidin™, which was used for
affinity capture ofbiotinylated PEGylated liposomes. NeutrAvidin™ was either
covalently bound onto polymer surfaces via plasma (glow discharge) polymer coating
and layers of carboxylated polymers (polyacrylic acid or carboxymethyl-dextrans) or
affinity "docked" onto a PEG-Biotin gel interlayer. Detailed surface analyses (mainly
X-ray Photoelectron Spectroscopy (XPS) and Atomic Force Microscopy (AFM)) were
used to characterize and verify each step in the fabrication of the liposome coated
surfaces.
To test the in vitro efficacy ofliposome coated biomaterials, a compound known
to modulate angiogenesis was encapsulated in liposomes and these liposomes attached
onto solid surfaces. Results obtained with two in vitro angiogenesis model assays show
that effective inhibition of angiogenesis was achieved with suitably constructed surfacebound
liposome implants.
The results presented in this thesis show that surface attachment of liposomes to
modified polymers is feasible. Moreover, surface-bound liposomes can be successfully
used as a drug delivery system to inhibit angiogenesis.